Professor Thomas Jaki and the city of Wuhan, China
A Lancaster University statistician who worked on the first published large randomised clinical trial for a potential treatment for the COVID-19 virus said the scientific community was coming together to combat the coronavirus.
There are currently no specific treatments for COVID-19. However, it is possible that some existing drugs, usually used for other conditions, may have some benefits.
The results were quite encouraging, which has led to further studies taking place and I would expect to see these treatments to be introduced into routine care, in some cases, in the coming weeks.
Professor Thomas Jaki, from the Medical and Pharmaceutical Statistics Research Unit in the Department of Mathematics and Statistics at Lancaster University, said the initial trial in Wuhan, China, investigated whether anti-viral drugs used to treat HIV would relieve the symptoms of COVID-19 – and started when there were less than 500 confirmed cases worldwide.
The trial saw 199 COVID-19 patients at Jin Yin-Tan Hospital treated either using standard of care or being given lopinavir–ritonavir. The results were published recently and showed enough promise that further, larger trials of the lopinavir–ritonavir treatment have now been established.
Specifically, the trial showed that patients who were randomly chosen to receive lopinavir–ritonavir appeared to improve faster. Meanwhile, among those patients who actually received lopinavir–ritonavir, the time to clinical improvement was significantly shorter than in patients receiving standard of care alone. At the same time acceptable safety levels were observed.
Professor Jaki said: “The results were quite encouraging, which has led to further studies taking place and I would expect to see these treatments to be introduced into routine care, in some cases, in the coming weeks.”
The findings from this study will also be considered as part of the forthcoming Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial. This will provide a trial platform to evaluate some of the approximately 30 treatments which are currently believed to have potential for treatment of COVID-19. The chief investigator for that trial is Peter Horby, Professor of Emerging Infectious Diseases and Global Health in the Nuffield Department of Medicine at the University of Oxford – who was also part of the initial study in Wuhan.
Professor Jaki said the fact these studies were taking place during a medical emergency had seen a determination to move things forward at pace.
He added: “The astonishing thing about the RECOVERY trial is the speed with which it got off the ground, from the initial agreement being received from the Department of Health and Social Care it was just nine days before the first patient was recruited. That process would usually take between six and nine months.
“We have benefitted by learning from trials in China – keep it simple. RECOVERY uses a very short protocol and attempts to minimise burden on staff in hospitals which are overwhelmed, so we have tried to ensure data collection is simple. It is an important study and one which needs to be done quickly.
“This is one of the largest trials into treatments for COVID-19. There is a second large trial that is currently recruiting in the UK – REMAP-CAP – which is looking at impacts of treatments on severely ill patients, but both teams have worked together to ensure they will be able to learn as much as they can from both trials.
“This is unusual but a lot of the competitive nature of these things isn’t there at the moment. We all have the same goal.”
The RECOVERY trial has been classed as an Urgent Public Health Research Study. It is one of a round of projects to receive £10.5m as part of the £20m rapid research response funded by UK Research and Innovation, and by the Department of Health and Social Care through the National Institute for Health Research (NIHR).
Chief Medical Officer Professor Chris Whitty and NHS England Medical Director Professor Stephen Powis have written to NHS trusts in England asking them to fully support the new trial.
Professor Jaki is also one of the authors of an opinion piece published in the New England Medical Journal last week on an approach to clinical trials around large epidemics.
While the piece was predominantly written months before the coronavirus outbreak, it encourages greater collaboration between scientists and much of the advice is already being reflected in the World Health Organisation’s developing strategy.
Professor Jaki added: “This is the culmination of a conversation which started several years ago where the WHO recognised the necessity of pre-planning in the event of a disease outbreak.
“While it may sometimes feel like we are unprepared for incidents like the COVID-19 outbreak there is actually a co-ordinated global effort among scientists, and Lancaster plays its part in that.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Chest pain when breathing? Causes and treatment
Whether you are inhaling or exhaling, chest pains can be the result of serious medical conditions. Finding it hard to breathe can depend on factors like altitude, air quality, and what position your ...
- Japan's government to stop subsidizing COVID-19 treatment after March
Hospitals are making preparations to admit coronavirus patients to general wards and we think that is no problem,' said health minister Keizo Takemi.
- Japan gov't to stop COVID-19 treatment subsidies at end of March
The Japanese government said Tuesday it will cease subsidizing medical expenses for people infected with COVID-19, including no longe ...
- Covid-19 increases risk of developing autoimmune disease, but vaccination helps, large study shows
A large study in Japan and South Korea shows that Covid-19 increases risk of developing autoimmune disease, but vaccination helps.
- Mild Covid-19 infections make insomnia more likely, especially in people with anxiety or depression
Doctors already knew that a Covid-19 infection bad enough to hospitalize someone is often followed by insomnia, but a new study of patients with recent mild Covid-19 has shown that these patients are ...
Go deeper with Google Headlines on:
[google_news title=”” keyword=”COVID-19 treatment” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
- Boosted Atazanavir versus Lopinavir in Treatment-Experienced Patients
Ritonavir-boosted atazanavir and lopinavir had similar antiviral efficacy in this large study of treatment-experienced patients. Atazanavir (usually with ritonavir boosting) is becoming an ...
- Atazanavir in Treatment-Experienced Patients
Researchers reported results from Study 043, a randomized, open-label trial comparing atazanavir (400 mg daily) with lopinavir/ritonavir (400mg/100mg) in patients with treatment failure on 1 PI ...
- Page settings
This combination product contains two medications: lopinavir and ritonavir. This product is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in ...
- Birth Outcomes for Pregnant Women with HIV Using Tenofovir–Emtricitabine
2 Pregnant women randomly assigned to receive tenofovir disoproxil fumarate, emtricitabine, and ritonavir-boosted lopinavir (TDF–FTC–LPV/r) were more than twice as likely to have infants born ...
- Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection
Lopinavir is a newly developed inhibitor of human immunodeficiency virus (HIV) protease that, when formulated with ritonavir, yields mean trough plasma lopinavir concentrations that are at least ...
Go deeper with Google Headlines on:
[google_news title=”” keyword=”lopinavir–ritonavir” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]